Everolimus News and Research

RSS

Phase III trial reports positive results with HDAC inhibitor in advanced breast cancer patients

Epigenetic therapy with histone deacetylase inhibitors is worth pursuing in hormone receptor positive advanced breast cancer, suggests a phase III trial reported today at the ESMO 2018 Congress in Munich.

22 Oct 2018

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis, Inc. today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC). The findings are being presented this week at the European Society for Medical Oncology 2018 Congress being held October 19-23 in Munich, Germany.

22 Oct 2018

Drug treatment at a young age could help reverse autism-like behavior in tuberous sclerosis

New research on autism has found, in a mouse model, that drug treatment at a young age can reverse social impairments. But the same intervention was not effective at an older age.

10 Oct 2018

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

24 Sep 2018

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.

19 Sep 2018

Drug coated balloons are as good as stent implants for treating small blocked arteries

A removable balloon is as good as a permanent stent implant for opening small blocked arteries, according to late breaking results from the BASKET-SMALL 2 trial presented in a Hot Line Session today at ESC Congress 2018 and simultaneously published in The Lancet.

28 Aug 2018

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the European Commission has granted a marketing authorization for the oral receptor tyrosine kinase inhibitor LENVIMA (lenvatinib mesylate) as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.

23 Aug 2018

Unbiased approach reveals how to restore breast cancer drugs’ tumor-killing potential

More than 60 percent of breast cancer cases involve defects in the same biochemical chain of events within cancer cells-- known as the PI3 kinase (PI3K) pathway--but efforts to develop therapies targeting this pathway have met with little success after hundreds of mostly failed clinical trials. And researchers still don't understand why.

26 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

New targeted treatment could benefit patients with certain pancreatic tumors

Researchers at the University of Cincinnati College of Medicine have shown that a new targeted treatment could benefit patients with certain pancreatic tumors by preventing spread of the cancer and protecting their heart from damage--a direct result of the tumor.

1 Dec 2017

Abbott receives CE Mark for newest generation of drug-eluting XIENCE coronary stent system

Abbott today announced it received CE Mark for XIENCE Sierra, the newest generation of the company’s gold-standard XIENCE everolimus-eluting coronary stent system.

31 Oct 2017

Lab-grown miniature blood vessels mimic rare Hutchinson-Gilford Progeria Syndrome

Biomedical engineers have grown miniature human blood vessels that exhibit many of the symptoms and drug reactions associated with Hutchinson-Gilford Progeria Syndrome -- an extremely rare genetic disease that causes symptoms resembling accelerated aging in children.

16 Aug 2017

Novartis to collaborate with IBM Watson Health for improving outcomes in advanced breast cancer

Novartis today announced a first-of-its-kind collaboration with IBM Watson Health on an initiative to optimize cancer care and improve patient outcomes.

5 Jun 2017

Liver transplant patients who take new anti-rejection drug gain less weight, study finds

Researchers have discovered that a new anti-rejection drug that is gentler on the kidneys after liver transplant also reduces weight gain, which is common after surgery and can lead to serious complications for transplant patients.

3 May 2017

Stents can be as effective as surgery for many patients with left main coronary artery disease

A major international study has found that drug-eluting stents, a less-invasive alternative to bypass surgery, are as effective as surgery for many patients with a blockage in the left main coronary artery.

1 Nov 2016

ATS releases new clinical practice guidelines for diagnosis, management of LAM

The American Thoracic Society and the Japanese Respiratory Society have published new clinical practice guidelines for the diagnosis and management of lymphangioleiomyomatosis (LAM), a rare lung disease that primarily affects women of child-bearing age.

15 Sep 2016

Everolimus News and Research

Phase III trial reports positive results with HDAC inhibitor in advanced breast cancer patients

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Drug treatment at a young age could help reverse autism-like behavior in tuberous sclerosis

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Drug coated balloons are as good as stent implants for treating small blocked arteries

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

Unbiased approach reveals how to restore breast cancer drugs’ tumor-killing potential

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

New targeted treatment could benefit patients with certain pancreatic tumors

Abbott receives CE Mark for newest generation of drug-eluting XIENCE coronary stent system

Lab-grown miniature blood vessels mimic rare Hutchinson-Gilford Progeria Syndrome

Novartis to collaborate with IBM Watson Health for improving outcomes in advanced breast cancer

Liver transplant patients who take new anti-rejection drug gain less weight, study finds

Stents can be as effective as surgery for many patients with left main coronary artery disease

ATS releases new clinical practice guidelines for diagnosis, management of LAM

New generation drug eluting stents show lower efficacy than contemporary BMS, study shows

New drug provides considerable added benefit in treating adults with advanced renal cell cancer

FDA approves Absorb GT1 BVS to treat coronary artery disease

Neoadjuvant endocrine therapy 'a reasonable option' for ER-positive breast cancer

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News